Related Experiment Video
Updated: Jul 30, 2025
06:08
Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
Published on: June 2, 2023
1.8K
Lenvatinib as a Promising Treatment Option for Unresectable Hürthle Cell Carcinoma: A Case Report
Parth S Shirode1, Anil D'cruz1, Sataksi Chatterjee1
1Head and Neck Surgery, Apollo Hospitals, Navi Mumbai, IND.
Cureus
|May 15, 2023
Summary
Hürthle cell carcinoma (HCC) is an aggressive thyroid cancer. Lenvatinib, a tyrosine kinase inhibitor, effectively managed a locally advanced, metastatic HCC case, showing a 30-month progression-free survival.
Area of Science:
- Oncology
- Endocrinology
Background:
- Hürthle cell carcinoma (HCC) presents a more aggressive clinical course compared to other differentiated thyroid cancers (DTCs), often associated with higher rates of distant metastases.
- Surgical intervention for locally advanced HCC is challenging due to invasion of critical neck structures, increasing recurrence risk.
Observation:
- A 37-year-old male presented with locally advanced, widely metastatic HCC encasing the left carotid sheath and recurrent laryngeal nerve.
- Diagnostic imaging confirmed HCC with lung and spine metastases.
Findings:
- Lenvatinib, a tyrosine kinase inhibitor (TKI), was administered as a first-line treatment for unresectable, radio-iodine refractory metastatic DTC.
- The patient achieved a progression-free duration of 30 months, with significant tumor size reduction, indicating a positive response to lenvatinib therapy.
Implications:
- This case highlights the efficacy of lenvatinib in managing advanced, unresectable Hürthle cell carcinoma.
- Tyrosine kinase inhibitors represent a crucial management strategy for advanced DTC, improving prognosis and survival rates in challenging cases.
